The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals

Scandinavian Journal of Immunology

Volumn 52, Issue 3, 2000, Pages 298-303

  Nielsen, ^a,a,b,b,c,c   SoRensen ^a,b,c   Aladdin, ^a,b,c   ErsboLl ^a,b,c   Mathiesen, ^a,b,c   Ullum, ^a,b,c   Gerstoft, ^a,b,c   Pedersen, ^a,b,c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL; THROMBOCYTE COUNT;

ANTI-HIV AGENTS; BLOOD CELL COUNT; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; FEMALE; FILGRASTIM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PLATELET COUNT; TIME FACTORS;

EID: 0033863219     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00774.x     Document Type: Review

References (33)

1. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine
2. Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoitin in asymptomatic HIV patients
3. Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor
4. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study
5. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes
6. + hematopoietic stem cells of HIV-infected individuals
7. + peripheral blood stem cells from asymptomatic human immunodeficiency vires type-1-infected individuals mobilized with granulocyte colony-stimulating factor
8. Recombinant human granulocyte colony-stimulating factor increases circulating CD34-positive cells in patients with AIDS
9. Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: Increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy
10. + progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type I-infected adults
11. Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals
12. G-CSF increases CD4+ T-cell counts in HIV-infected patients on stable HAART. Results from a randomized, placebo-controlled trial
13. Immunological and virological changes in antiretroviral naive HIV infected patients randomised to G-CSF or placebo simultaneously with initiation of HAART
14. Filgrastim restores interleukin-2 production in blod from patients with advanced human immunodeficiency virus infection
15. + T cell homeostasis and function in advanced HIV disease
16. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities
17. Immunological effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection
18. Biphsic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A compositie of redistribution and proliferation
19. Viral dynamics in human immunodeficiency virus type I infection
20. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
21. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults
22. T cell progenitor function during progressive HIV-1 infection and after anti-retroviral therapy
23. Highly active antiretroviral therapy HAART normalizes the function of progenitor cells in human immunodeficiency virus HIV-infected patients
24. Treatment with granulocyte-colony stimulating factor decreases the capacity of hematopoietic progenitor cells for generation of lymphocytes in human immunodeficiency virus-infected persons
25. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
26. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals
27. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients
28. Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus
29. Granulocyte colony-stimulating factor: Its potential role in infectious disease
30. Prevention of bacterial infections in patients with advanced HIV infection
31. Granulocyte colony-stimulating factor mobilizes primitive hematopoietic stem cells in normal individuals
32. Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells
33. Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration